Pregnancy and Hepatitis B Virus Infection

Chronic hepatitis B virus (HBV) infection due to mother-to-child transmission during perinatal period remains as an important global health problem. Being infected with HBV at early ages is associated with increased risk of chronic disease. Therefore, hepatitis B surface antigen (HBsAg)-positive mot...

Full description

Bibliographic Details
Main Author: Selma TOSUN
Format: Article
Language:Turkish
Published: Galenos Yayinevi 2016-12-01
Series:Mediterranean Journal of Infection, Microbes and Antimicrobials
Subjects:
Online Access:http://www.mjima.org/pdf.php?&id=69
_version_ 1797911030431481856
author Selma TOSUN
author_facet Selma TOSUN
author_sort Selma TOSUN
collection DOAJ
description Chronic hepatitis B virus (HBV) infection due to mother-to-child transmission during perinatal period remains as an important global health problem. Being infected with HBV at early ages is associated with increased risk of chronic disease. Therefore, hepatitis B surface antigen (HBsAg)-positive mothers must be immunized with HBV vaccine and hepatitis B immunoglobulin (HBIG). Despite standard passive-active immunoprophylaxis with HBIG and HBV vaccine in neonates, some of these newborns still acquire HBV infection. The aim of this paper was to review the literature on the risk factors associated with HBV infection in infants born to HBsAg-positive women, effects of HBsAg positivity on mother and infants, practices, and follow-up algorithms to be done during and after pregnancy and childbirth. We analyzed review articles, original articles and case reports related to HBsAg positivity during pregnancy published in the last five year. In many countries, investigation of HBsAg during pregnancy is not at the desired levels. Babies of mothers whose HBV serology is not checked during pregnancy, may develop chronic disease because of incomplete immunization.Hepatitis B e-antigen positivity and HBV DNA levels greater than 106 IU/ml in pregnancy as well as presence of chronic HBV infection in older sibling are important risk factors for transmission of HBV to infant in pregnancy. Despite standard passive-active immunoprophylaxis with HBIG and hepatitis B vaccine in neonates, some of these newborns still acquire HBV infection. Therefore, in pregnant women with a serum HBV DNA level of >106 IU/ml, lamivudine, telbivudine or tenofovir could be started in the third trimester to further reduce the transmission rate. As a result, the risk of premature birth, premature membrane rupture and hemorrhage is higher in HBsAg-positive pregnant women than in HBsAg-negative pregnant women. There are contradictory publications and reviews on the effect of delivery mode on the transmission of HBV infection. However, cesarean birth is more recommended to reduce the risk of mother-to-child transmission. In conclusion, all pregnant women must be tested for HBV infection during pregnancy and babies born to HBsAg-positive mother should be immunized with HBV vaccine and HBIG. For pregnant women with a serum level of HBV DNA >106-7 IU/ml antiviral therapy may be started to further reduce the transmission rate.
first_indexed 2024-04-10T11:33:54Z
format Article
id doaj.art-19db63388e5249f78c61ebd9570324f2
institution Directory Open Access Journal
issn 2147-673X
language Turkish
last_indexed 2024-04-10T11:33:54Z
publishDate 2016-12-01
publisher Galenos Yayinevi
record_format Article
series Mediterranean Journal of Infection, Microbes and Antimicrobials
spelling doaj.art-19db63388e5249f78c61ebd9570324f22023-02-15T16:17:56ZturGalenos YayineviMediterranean Journal of Infection, Microbes and Antimicrobials2147-673X2016-12-01510.4274/mjima.2016.4Pregnancy and Hepatitis B Virus InfectionSelma TOSUN0Bozyaka Eğitim ve Araştırma Hastanesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, İzmir, TürkiyeChronic hepatitis B virus (HBV) infection due to mother-to-child transmission during perinatal period remains as an important global health problem. Being infected with HBV at early ages is associated with increased risk of chronic disease. Therefore, hepatitis B surface antigen (HBsAg)-positive mothers must be immunized with HBV vaccine and hepatitis B immunoglobulin (HBIG). Despite standard passive-active immunoprophylaxis with HBIG and HBV vaccine in neonates, some of these newborns still acquire HBV infection. The aim of this paper was to review the literature on the risk factors associated with HBV infection in infants born to HBsAg-positive women, effects of HBsAg positivity on mother and infants, practices, and follow-up algorithms to be done during and after pregnancy and childbirth. We analyzed review articles, original articles and case reports related to HBsAg positivity during pregnancy published in the last five year. In many countries, investigation of HBsAg during pregnancy is not at the desired levels. Babies of mothers whose HBV serology is not checked during pregnancy, may develop chronic disease because of incomplete immunization.Hepatitis B e-antigen positivity and HBV DNA levels greater than 106 IU/ml in pregnancy as well as presence of chronic HBV infection in older sibling are important risk factors for transmission of HBV to infant in pregnancy. Despite standard passive-active immunoprophylaxis with HBIG and hepatitis B vaccine in neonates, some of these newborns still acquire HBV infection. Therefore, in pregnant women with a serum HBV DNA level of >106 IU/ml, lamivudine, telbivudine or tenofovir could be started in the third trimester to further reduce the transmission rate. As a result, the risk of premature birth, premature membrane rupture and hemorrhage is higher in HBsAg-positive pregnant women than in HBsAg-negative pregnant women. There are contradictory publications and reviews on the effect of delivery mode on the transmission of HBV infection. However, cesarean birth is more recommended to reduce the risk of mother-to-child transmission. In conclusion, all pregnant women must be tested for HBV infection during pregnancy and babies born to HBsAg-positive mother should be immunized with HBV vaccine and HBIG. For pregnant women with a serum level of HBV DNA >106-7 IU/ml antiviral therapy may be started to further reduce the transmission rate.http://www.mjima.org/pdf.php?&id=69Pregnancyhepatitis B surface antigenoral antiviral agents
spellingShingle Selma TOSUN
Pregnancy and Hepatitis B Virus Infection
Mediterranean Journal of Infection, Microbes and Antimicrobials
Pregnancy
hepatitis B surface antigen
oral antiviral agents
title Pregnancy and Hepatitis B Virus Infection
title_full Pregnancy and Hepatitis B Virus Infection
title_fullStr Pregnancy and Hepatitis B Virus Infection
title_full_unstemmed Pregnancy and Hepatitis B Virus Infection
title_short Pregnancy and Hepatitis B Virus Infection
title_sort pregnancy and hepatitis b virus infection
topic Pregnancy
hepatitis B surface antigen
oral antiviral agents
url http://www.mjima.org/pdf.php?&id=69
work_keys_str_mv AT selmatosun pregnancyandhepatitisbvirusinfection